Overview

• Pharmaceutical firm's Q4 revenue rose 10%

• Adjusted EPS for Q4 beat analyst expectations

• Company provides 2026 adjusted EPS guidance of $14.37 to $14.57

Outlook

• AbbVie issues 2026 adjusted diluted EPS guidance of $14.37 to $14.57

• Company expects robust growth in 2026 driven by strong fundamentals

Result Drivers

• IMMUNOLOGY GROWTH - AbbVie reported a significant increase in immunology portfolio revenues, driven by Skyrizi and Rinvoq, which grew by 32.5% and 29.5% respectively

• NEUROSCIENCE PERFORMANCE - Neuroscience portfolio revenues rose by 17.9%, with notable contributions from Vraylar and Qulipta

• ONCOLOGY CHALLENGES - Oncology portfolio faced a decline in Imbruvica revenues, which decreased by 20.8%

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for AbbVie Inc is $245.00, about 8.6% above its February 3 closing price of $225.66

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nPn2rBnnla

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)